FCG Investment Co Has $583,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

FCG Investment Co decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 819 shares of the biopharmaceutical company’s stock after selling 205 shares during the quarter. FCG Investment Co’s holdings in Regeneron Pharmaceuticals were worth $583,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Avior Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals by 29.1% during the fourth quarter. Avior Wealth Management LLC now owns 1,190 shares of the biopharmaceutical company’s stock worth $848,000 after acquiring an additional 268 shares during the last quarter. Traynor Capital Management Inc. raised its holdings in Regeneron Pharmaceuticals by 10.7% during the 4th quarter. Traynor Capital Management Inc. now owns 24,790 shares of the biopharmaceutical company’s stock worth $17,659,000 after purchasing an additional 2,400 shares during the last quarter. Hudson Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 7.8% during the 4th quarter. Hudson Capital Management LLC now owns 4,961 shares of the biopharmaceutical company’s stock valued at $3,534,000 after purchasing an additional 357 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of Regeneron Pharmaceuticals by 21.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,066 shares of the biopharmaceutical company’s stock valued at $16,431,000 after purchasing an additional 4,130 shares during the last quarter. Finally, BDF Gestion acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $1,956,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Oppenheimer cut their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Finally, Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Up 2.1 %

Regeneron Pharmaceuticals stock opened at $694.64 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a fifty day simple moving average of $730.57 and a 200 day simple moving average of $942.10. The company has a market cap of $76.33 billion, a P/E ratio of 17.19, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.